 | |
| Company type | Subsidiary |
|---|---|
| NYSE: AGN | |
| Industry | Pharmaceuticals |
| Predecessors | Allergan, Inc. and Actavis before the 2015 tax inversion and merger |
| Founded | May 16, 2013, upon the combination of Allergan Finance, LLC (Actavis) & Warner Chilcott March 17, 2015 renamed to Allergan Plc upon the merger of Allergan, Inc and Actavis |
| Headquarters | Clonshaugh Business & Technology Park, Coolock, D17 E400, , |
Number of locations | 40 manufacturing facilities, 27 global R&D centres and marketing/sales facilities worldwide. |
Area served | ~100 countries |
| Products | Branded pharmaceuticals |
| Revenue |  $16.089 billion (2019) |
 -$5.142 billion (2018) | |
| Total assets | $94.699 billion (2019) |
| Total equity | $58.195 billion (2019) |
Number of employees | 17,800 (2018) |
| Parent | AbbVie |
| Website | www |
| Footnotes / references [1] | |
Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.[1][2][3] The company is the maker of Botox.[1]
Allergan plc was formed in March 2015 when Irish–registered Actavis plc acquired U.S.–registered Allergan, Inc., and assumed the Allergan name.[4][5] In 2016, Allergan sold its generic drugs business, Actavis, to Teva Pharmaceuticals for $40.5 billion.[6]
In June 2019, U.S. pharmaceutical company AbbVie announced it had reached an agreement to acquire Allergan for $63 billion. The merged company would be domiciled in the U.S. for tax purposes.[7][8]
- ^ a b c "Allergan plc 2018 Form 10-K Annual Report". U.S. Securities and Exchange Commission.
- ^ Rockoff, Jonathan D. (11 February 2018). "New Tax Law Haunts Inversion Deals". The Wall Street Journal.
Similarly, Allergan, a drugmaker that moved its headquarters to Ireland after a 2013 acquisition but gets about 80% of revenue in the U.S., expects the loss of deductions on intercompany loans will largely be balanced out by lower taxes on its U.S. sales.
- ^ Rockoff, Jonathan D. (2018-05-30). "Allergan To Sell Businesses in Bid To Appease Shareholders". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-04-07.
- ^ "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune. 30 July 2015.
For a master class in mergers and acquisitions, one need only look at the company formerly known as Actavis. Now called Allergan, after its $70 billion acquisition of that maker of Botox last fall, the pharmaceutical firm has undertaken a dizzying series of deals in just the last few years, reinventing and renaming itself in a fashion that might make the artist formerly known as The Artist Formerly Known As Prince proud.
- ^ Haggerty, Neil (2015-06-15). "Actavis Changes Name to Allergan After Deal For Botox Maker". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-04-07.
- ^ "Why Teva's $40 Billion Deal for Allergan's Generic Drugs Is Being Delayed". Fortune. Retrieved 2020-04-07.
- ^ Julia Kollewe (25 June 2019). "Botox maker Allergan bought by US drug giant for $63bn". The Guardian. Retrieved 25 June 2019.
- ^ Rebecca Spalding; Riley Griffin (25 June 2019). "AbbVie Strikes $63 Billion Deal for Botox Maker Allergan". Bloomberg.com. Bloomberg News. Retrieved 25 June 2019.
The deal will return Allergan to the U.S., at least for tax purposes.